Theralase Advanced Cancer Therapy Research Recognized at Major International Conference

Toronto, Ontario – May 16, 2013, Theralase Technologies Inc. (TSXV: TLT) (“Theralase”) announced today that its researchers have discovered a significant new mechanism of action for a new class of Photo Dynamic Compounds (PDCs), that have been custom designed to destroy cancer cells when activated by a proprietary light source.

The preclinical study, conducted by Theralase scientists and their colleagues at University Health Network’s Princess Margaret Cancer Centre, was presented on May 15, at the Laser World of Photonics conference held in Munich, Germany.

In previous preclinical studies, Theralase’s PDCs have been proven to be promising anti-cancer agents in various cancer models. Their efficacy involved a number of critical cellular processes, including DNA damage and programmed cell death. All PDCs were thought to work primarily by oxygen-dependent mechanisms, ultimately causing cell death in the presence of highly reactive oxygen. In this study; however, scientists established that a new class of Theralase PDCs have an additional “oxygen independent” mechanism of action, which would increase efficacy in the destruction of more clinically aggressive tumours.

The research lead by Dr. Lothar Lilge, Senior Scientist, Ontario Cancer Institute, Princess Margaret Cancer Centre and Dr. Arkady Mandel, Chief Scientific Officer, Theralase has shown that specific metal-based PDCs when tested for effectiveness of cancer destruction in a low oxygen environment were proven to be highly effective in the destruction of human brain cancer cells in-vitro, thus activating this newly discovered pathway. Additionally using this pathway, Theralase scientists confirmed in a preclinical model a complete response rate and the destruction of subcutaneous (under the skin) colon cancer tumours in mice, which were treated with Theralase’s anti-cancer PDC technology. On follow-up, the initial complete response was maintained in two-thirds of the animals for over 1 year without recurrence.

Roger Dumoulin-White, President and CEO of Theralase Technologies Inc. stated, “Recognition of our world class anti-cancer research at the Munich conference is another testament to the cutting edge research our scientists are conducting in this field. Our findings would strongly suggest that Theralase’s PDCs oxygen independent potency would significantly enhance our ability to destroy cancer cells. Tumours in a low oxygen environment have been extremely challenging because this lack of oxygen renders solid tumours much more resistant to therapeutic interventions. Many traditional therapeutic agents, conducted on poorly oxygenated solid core tumours, including any currently FDA approved PDCs, are susceptible to a “self-limiting” activity; whereby, below a critical threshold oxygenation level, their efficacy is progressively reduced resulting in minimal to no cancer cell destruction. This new class of Theralase PDCs are not susceptible to this “self-limiting” activity and as a result maintain their efficacy even in extremely low oxygenated cancerous tumours, such as breast and prostate cancer. As a result, Theralase is extremely excited about the latest research and what it means in the field of cancer destruction. Theralase is committed to the early commercialization of its patented light activated Photo Dynamic Compounds in the areas of anti-cancer and anti-bacterial applications to generate substantial revenues for the Company and hence dramatically increase shareholder value.”

About Theralase Technologies Inc.

Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralase technology is safe and effective in treating pain, inflammation and for tissue regeneration of neural muscular skeletal conditions Theralase is currently developing patented Photo Dynamic Compounds (PDCs) that are able to target and destroy cancers, bacteria and viruses when light activated by Theralase’s proprietary laser technology.

For further information please visit www.theralase.com , regulatory filings may be viewed by visiting www.sedar.com.

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

For More Information, please contact:

Roger Dumoulin-White,                                                                      

President & CEO                                                                                  

416-699-LASE (5273) ext. 225                                                              

rwhite@theralase.com

Kristina Hachey

Chief Financial Officer

416-699-LASE (5273) ext. 224

khachey@theralase.com                                                                     

Greg Bewsh

Director of Investor Relations

416-699-LASE (5273) ext. 258

gbewsh@theralase.com  

Arkady Mandel

Chief Scientific Officer

416-699-LASE (5273) ext. 260

amandel@theralase.com

Theralase Compound Effective in Destroying Bladder Cancer Tumour Cells

Toronto, Ontario –November 12, 2012 -- Theralase Technologies Inc. (TSX-V: TLT) Photo Dynamic Therapy (PDT) Division, announced today study results proving that its patented Photo Dynamic Compounds (PDCs)  were significantly more effective in destroying a human urinary bladder carcinoma cell line than a FDA approved photosensitizer, aminolevulinic acid (ALA).

Dr. Arkady Mandel, Chief Scientific Officer of Theralase stated, “Commercialization of any new anti-cancer medicine depends upon the safe and effective destruction of all cancerous tumours, while upholding the patient’s quality of life. We are excited that our leading compound effectively destroyed a human urinary bladder carcinoma cell line (HT-1376) when activated by our proprietary light system. To validate our initial success, we evaluated the efficacy of the Theralase PDC in comparison with aminolevulinic acid (ALA). The results indicated that the Theralase PDC was effectively destroying bladder cancer cells at much lower concentrations than ALA (1/1000^th of the dose).”

Dr. Lothar Lilge, Professor and Senior Scientist, Ontario Cancer Institute, Princess Margaret Cancer Centre, University Health Network stated, “In my lab, the Theralase PDCs have shown remarkable efficacy and robustness in the destruction of various cancer cell lines, such as: colon, brain, breast and now bladder cancer. This research potentially offers a new opportunity for individualized cancer therapy across various invasive tumours.”

Roger Dumoulin-White, President and CEO, Theralase Inc. stated, “Based upon our recent success, we have now reconfirmed that bladder cancer is our lead cancer target for our lead PDC compound. Our research confirms what we had already suspected; our PDC technology is lethal to human urinary bladder carcinoma cells. Given that our technology can deliver effective results at significantly lower doses than ALA, this would suggest a superior safety and cost effectiveness for our lead compound, as compared to ALA. We are confident that as we complete our preclinical research and prepare for human trials in 2013, we will demonstrate to the medical community that we possess a highly effective, safe and efficient alternative treatment option to current bladder cancer patients.”

Bladder cancer is the fifth most common cancer in the North America; the fourth most common among men and eighth most common in women. In the United States 73,000 new bladder cancer cases and 15,000 deaths are reported annually. With a recurrence rate of nearly 80%, bladder cancer is the most expensive cancer to treat on a per patient basis. The high recurrence rate severely affects the quality of life of patients and also the total cost of treatment, which in the United States exceeds $2.9 billion in direct treatment related costs annually.

In other related news, Sun Pharmaceutical Industries (NSE: SUNPHARMA, BSE: 524715), with a market value of $USD 13.3 billion, announced on November 8, 2012, that it signed a definitive agreement to acquire Dusa Pharaceuticals Inc. (DUSA) for $8 per share for a total cash consideration of $USD 230 million. DUSA is a dermatology company focused on developing and marketing its FDA approved Levulan photodynamic therapy platform (active ingredient of Levulan is ALA), for actinic keratosis of the face or scalp (dry, scaly patches on the skin that can lead to skin cancer). http://www.sunpharma.com/news/press/20121108%20Sun%20Pharma%20to%20Acquire%20DUSA%20.pdf

About Theralase Technologies Inc.:

Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralase technology is safe and effective in treating pain, inflammation and for tissue regeneration of neural muscular skeletal conditions and wound healing. Theralase is currently developing patented Photo Dynamic Compounds (PDCs) that are able to target and destroy cancers, bacteria and viruses when light activated by Theralase’s proprietary and patented laser technology.

 For further information please visit www.theralase.com , regulatory filings may be viewed by visiting www.sedar.com.

 

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

For More Information

Roger Dumoulin-White                                                                                   

President & CEO                         

416-447-8455 ext. 225                                          

rwhite@theralase.com

Kristina Hachey

Chief Financial Officer

416-447-8455 ext. 224

khachey@theralase.com 

Arkady Mandel

Chief Scientific Officer

416-447-8455 ext. 242

amandel@theralase.com

Greg Bewsh

Director of Investor Relations

416-447-8455 ext. 262

gbewsh@theralase.com   

Theralase Identifies the First Cancer Target for its Advanced Photo Dynamic Therapy

Theralase to Focus Research on Bladder Cancer in Clinical Trials

Toronto, Ontario – July 18, 2012, Theralase Technologies Inc. (TSX-V: TLT) announced today that it has selected bladder cancer as the first clinical target in its Novel Photo Dynamic Compound (PDC) research. Theralase now has a clear direction with which to proceed with FDA Clinical Trials.

Bladder cancer is the fifth most common cancer in North America being the fourth most common in men and the eighth most common in woman. In North America, it is estimated that there will be over 77,000 new cases and over 15,000 deaths annually. "With a recurrence rate of nearly 80%, bladder cancer is the most expensive cancer to treat on a per patient basis," says Dr. Michael Jewett, a specialist in uro-oncology and member of Bladder Cancer Canada's Medical Advisory Board. "The high recurrence rate raises many issues affecting quality of life."

Dr Arkady Mandel, Chief Scientific Officer of Theralase said, “We have successfully continued development of the innovative anticancer platform technology that will be first tested in the models of bladder cancer in our labs.  Besides the strong scientific and clinical rationale for successful therapeutic application of Theralase’s advanced phototherapy in this patient population”, continued Dr. Mandel, “there have been no significant advances in bladder cancer treatment in several decades.  We are hopeful that the highly promising results of our research will move the field forward. Bladder cancer is a significant health concern. It is estimated that $2.9 billion is spent in the United States alone each year on the treatment of bladder cancer. We feel our technology will prove as effective in bladder cancer preclinical trials that will eventually lead to FDA clinical approval.”

July has been designated as “Bladder Cancer Awareness Month” in North America and we pray that our announcement is both timely and provides hope for the patients stricken with this devastating disease,” said Roger Dumoulin-White, President and CEO of Theralase. He added, “The Theralase light activated PDC drug has been proven to be superior to any currently approved FDA PDC drug on the market, tested in our lab and we are working hard to help eliminate this devastating disease that can dramatically affect so many families. Theralase plans to aggressively pursue commercialization of our ground-breaking PDC technology through the accelerated FDA regulatory approval process.  This FDA process is able to "fast-track" approval when a treatment is shown, through proven success rate, to have a positive impact on a serious, life-threatening medical conditions for which no other drug or treatment exists or is as effective.”

About Theralase Technologies Inc.

Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralase technology is safe and effective in treating pain, inflammation and for tissue regeneration of neural muscular skeletal conditions and wound healing in both humans and animals. Theralase complies with all FDA, Health Canada, CE and international regulatory approvals to ensure effective, safe and high quality products. Theralase also develops patented Photo Dynamic Compound (PDC) technology focused at targeting and destroying cancers, bacteria and viruses when light activated by Theralase’s proprietary and patented laser technologies.

For further information please visit www.theralase.com  , regulatory filings may be viewed by visiting www.sedar.com.

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

Theralase Establishes Middle East Distribution Network

Theralase Executes Distribution Agreement with Large Middle East Medical Distributor to Sell Therapeutic Lasers

Toronto, Ontario, Canada – May 30, 2012, Theralase Technologies Inc. (TSXV: TLT) announced today that it has entered into an exclusive distribution agreement with Jordan based medical device distributor MediQu to market and sell the Theralase line of therapeutic medical lasers into the Middle East, branded as Theralase Arabia.

Under the terms of the agreement, MediQu will exclusively market and sell the Theralase therapeutic medical laser technology in Jordan, Lebanon, Syria, Iraq, Saudi Arabia, Kuwait, United Arab Emirates, Bahrain, Qatar, Yemen, Oman, Egypt, Sudan, Libya, Algeria, Tunisia, Mauritania and Morocco, in exchange for achievement of certain minimum performance criteria. The current term of the agreement specifies minimum performance criteria of $USD 5 million ramping up over the next 5 years with exclusivity extended into further 5 year terms with annual performance criteria.

Roger Dumoulin-White, President and CEO of Theralase Inc. stated that “MediQu is a large medical device distribution company in the Middle East that has partnered with Theralase to establish Theralase Arabia bringing to the table an impressive array of government, commercial and medical contacts. The Middle East represents a population of 384 million, located in 17 countries with a total GDP of approximately $2.3 trillion and a medical device market that exceeds $5 billion annually according to 2009 statistics. MediQu has established a distribution network that provides sales, marketing and service coverage to customers in 16 of those countries, allowing Theralase Arabia the ability to market, sell and service the Theralase brand of therapeutic medical lasers to this lucrative market. Theralase Arabia expects to exceed USD $5 million annually in the Middle East within 3 to 5 years of launch.”

Roger Dumoulin-White, President & CEO of Theralase went on to say, “Theralase has provided initial training to MediQu’s sales, technical and clinical personnel at our inaugural launch into the region at the 4^th Biennial Emirates Physiotherapy Conference held in Dubai, United Arab Emirates on May 20 and 21, 2012.” He added, “We are currently negotiating with a number of other medical device distributors worldwide who have expressed an interest in marketing, selling and servicing the Theralase brand of superpulsed laser technology in their respective countries.”

Mr. Mohamed ALNabulsi, Project and Sales Manager of MediQu stated, “We were impressed with Theralase’s superpulsed laser system from the beginning and the dominance of the Theralase brand over the other competitive products we investigated. Theralase’s unrivalled scientific and clinical knowledge on the subject of therapeutic lasers was refreshing given the fact that most competitors we spoke to lacked the same understanding of the science. The Theralase technology was the only product on the market that we found that could activate all three known cellular pathways and provide a depth of penetration of four inches into tissue, promoting cellular regeneration at the source of tissue injury.  Initial testing at our key medical facilities in Jordan has been exceptional, with all patients treated experiencing significant pain relief, substantial inflammation reduction and accelerated healing. We are delighted to partner with Theralase to roll-out this technology to the rest of the Middle East countries we service. We have long term relationships with numerous major hospitals, medical clinics and doctors in the region and will be able to proactively promote the Theralase product line immediately. Alternative medicine is embraced in the Middle East and we feel confident that Theralase’s leading edge technology will be accepted and adopted at all levels of government and private medicine.”

About MediQu:

MediQu is the commercial trademark for Fatima for Medical device company servicing 16 countries in the Middle East region. MediQu possesses significant experience regarding sales, service, regional requirements and trade regulations of the various countries in which it does business. In addition, MediQu has built strong connections at the government, commercial and medical levels enabling it to generate strong sale leads, participate in government tenders and clearly communicate the clinical advantage of its products over other competitive products allowing it to dramatically increase market share of its represented products in the region.

About Theralase Technologies Inc.:

Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralase technology is safe and effective in treating pain, inflammation and for tissue regeneration of neural muscular skeletal conditions and wound healing in both humans and animals. Theralase complies with all FDA, Health Canada, CE and international regulatory approvals to ensure effective, safe and high quality products. Theralase also develops patented Photo Dynamic Compound (PDC) technology focused at targeting and destroying cancers, bacteria and viruses when light activated by Theralase’s proprietary and patented laser technologies.

For further information please visit www.theralase.com, regulatory filings may be viewed by visiting www.sedar.com.

This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

For More Information, please contact:

Roger Dumoulin - White,                                                                         

President and CEO                                                                                                  

416-447-8455 ext. 225                                                                              

rwhite@theralase.com

Kristina Hachey

Chief Financial Officer

416-447-8455 ext. 224

khachey@theralase.com                                                                         

Greg Bewsh

Director of Investor Relations

416-447-8455 ext. 262

gbewsh@theralase.com  

Arkady Mandel

Chief Scientific Officer

416-447-8455 ext. 242

amandel@theralase.com

Mohamed ALNabulsi

Manager

Theralase Arabia

+962 77777 30004

mnabulsi@theralasearabia.com

www.theralasearabia.com

Theralase to Present at BioFinance 2012 Life Sciences Conference

Toronto, Ontario – May 29, 2012, Theralase Technologies Inc. (TSXV: TLT) announced today that Roger Dumoulin-White, President and CEO will present the latest corporate information at the BioFinance 2012 conference being held in Toronto, Ontario from May 29 to 30, 2012.

BioFinance is a leading life sciences investor conference in Canada which showcases more than 60 diverse life science companies and the investment opportunities that they present. BioFinance 2012 also features 17 investor presentations that are aimed at addressing specific financing and management related issues relevant to life science industries.

Theralase’s presentation will take place Wednesday, May 30th at 3:00 pm in Company Presentation Room 1 at the St. Andrew’s Club and Conference Center. Mr. Roger Dumoulin-White, President and CEO of Theralase will present on the strategic direction and recent accomplishments of the company followed by a short Q&A period and longer one-on-one meeting period.

In other news, Mr. Dumoulin-White was recently interviewed on the TV show “The Next Biggest Winner” which is due to air on Ichannel on Tuesday, June 5^th at 7:30pm.  The Ichannel has over 1.3 million affluent Canadian subscribers who look to its business programming for investment opportunities. For a sneak preview, please visit http://youtu.be/y8VT6Rwp_gY

About Theralase Technologies Inc.:

Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralase technology is internationally approved in the safe and effective treatment of pain, inflammation and for the regeneration of tissue in neural muscular skeletal conditions in both humans and animals. Theralase is also researching and developing patented Photo Dynamic Compound (PDC) technology that is focused at targeting and destroying specific cancers, bacteria and viruses when light activated by Theralase’s proprietary and patented laser technologies.

For further information please visit www.theralase.com, regulatory filings may be viewed by visiting www.sedar.com.

This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

For More Information, please contact:

Roger Dumoulin - White,                                                                         

President & CEO                                                                                       

416-447-8455 ext. 225                                                                              

rwhite@theralase.com

Kristina Hachey

Chief Financial Officer

416-447-8455 ext. 224

khachey@theralase.com

Cold Lasers For an Aging Population:Geriatric Conditions chiropractic Toronto http://ping.fm/dF3sS

Free Webinar Jan 31 - Cold Laser for Foot and Ankle Injuries 1 CE Credit chiropractor chiropractic physio Toronto http://ping.fm/UMeOf